misclaiming-rd-tax-incentive

The following is a real case study drawn from BridgePoint Group’s work with an actual client. Names, identifying details and some specifics have been de-identified to protect client confidentiality. The situation and the outcome are genuine.

The Client

Industry: Pharmaceutical research
Location: NSW
Annual turnover: Approximately $4.5 million

The Situation

This client had been claiming the R&D Tax Incentive successfully for several years, using an outside advisor to prepare their annual application. The claims had always gone through without issue. But after lodging their application for this FY, the directors had a nagging feeling that something wasn’t quite right. Not that anything had failed, just a sense that the numbers deserved a closer look.

They reached out to BridgePoint Group to scope a second opinion on their R&D costing for the year. Like going to a specialist after visiting your GP, when you’re looking for a deeper, more detailed analysis.

A common R&D claim mistake

What BridgePoint Group found wasn’t an error so much as a pattern. The kind that shows up across many businesses that have been claiming R&DTI for years without a major incident.

The prior advisor’s process worked from the company’s profit and loss statement and a summary of salary and wages as the primary source of truth. Costs were assessed in broad strokes, line item by line item, each one simply marked in or out. What was missing was the layer underneath: a review of the individual transactions that made up those P&L balances, and, just as importantly, a documented rationale for why each cost was included or excluded.

Read | R&D Tax Incentive funding: How to reinvest 150% of your R&D expenditure back into R&D.

This is a far more common issue than most claimants realise. It doesn’t look like a mistake from the outside. The claim gets lodged, the refund arrives, nothing seems wrong. But a simplified, top-level approach to R&D costing tends to create three compounding problems, none of which show up until something forces a closer look.

  1. Under-Claiming or Over-Claiming
    Without detailed analysis, costs tend to get sorted by instinct rather than evidence, and that cuts both ways.

    In this case, the client had been under-claiming legitimate costs. Payroll tax and workers’ compensation insurance, both legitimate salary on-costs, had simply never been included. This eligible R&D expenditure was quietly left off the claim year after year.

    At the same time, the client had been over-claiming elsewhere, including costs like bank charges that had no genuine nexus to R&D activity. On their own, costs like this might seem immaterial. But collectively, they represent real exposure: if the ATO was ever to review the claim, costs included without a defensible connection to eligible R&D activity are exactly what a review would flag first.

    Under-claiming means leaving cash on the table. Over-claiming means exposing the business to risk. A business doing both simultaneously is often unaware it’s doing either

    Learn how to protect your R&D claims from ATO audits and AusIndustry reviews.
  1. Claiming Inaccurately and Missing Other Opportunities Entirely

    The second consequence is more subtle: a business that doesn’t understand its own numbers in detail often doesn’t realise which costs belong to R&DTI versus which costs belong somewhere else entirely.

    This client, for instance, had been including international travel costs in their R&D claim, which isn’t eligible for the R&DTI at all. What they didn’t know was that those same costs could potentially have been claimed under the Export Market Development Grant, a program they’d never heard of. The same pattern can apply to other Federal and State programs where costs that don’t belong in an R&D claim may still be fully claimable elsewhere.

    A business that treats R&D costing as a single, simplified exercise isn’t just risking its R&DTI claim. It’s very likely leaving other grant and incentive opportunities on the table without ever knowing they existed.
  1. Losing Visibility Over Your Own R&D Investment

    The third consequence is less about any single dollar figure and more about what a business can and can’t do with its numbers afterwards.

    A claim built on broad assumptions, rather than project-level detail, gives a business almost no usable insight into where its R&D investment is actually going. This client, it turned out, already had excellent underlying data: detailed timesheets showing exactly how much time each person spent across four distinct R&D projects. But that information had never been used in the claim itself.

    More importantly, once that level of detail exists, it becomes useful far beyond the R&D claim itself. A detailed, project-level breakdown lets management direct R&D investment with intent. It’s what a buyer expects to see during due diligence. And it gives investors and board members confidence that a material, recurring number, often one of the largest line items on the P&L, is accurate, defensible and consistent year on year, rather than a figure nobody can fully explain when questioned.

The Strategy

BridgePoint Group scoped an engagement to rebuild the client’s R&D costing from the ground up. Rather than relying on the profit and loss statement alone, the engagement pulled together the balance sheet, detailed profit and loss, itemised salary and wages (including employee start and end dates), the full general ledger, and the depreciation schedule. We built a costing workbook broken down project by project, with every inclusion and exclusion backed by documented analysis.

Read | R&D Tax Incentive: from application to cash refund, step by step.

The Outcome

The final claim landed broadly in line with prior years. However, this time built on a fundamentally different foundation. Every dollar in the claim had a documented reason for being there. Every dollar left out had a documented reason for its exclusion.

The client was initially surprised the figure wasn’t higher. That surprise quickly turned into confidence once they saw the depth of analysis behind it. This wasn’t a guess dressed up as a number. It was a defensible position the business could stand behind under scrutiny. And a dataset the business could actually use to understand where its R&D dollars were going.

For businesses already claiming R&DTI

The clearest risk in R&D often isn’t a business that’s never claimed before. It’s one that’s been claiming successfully for years and has never had a reason to question the process.

Have your source documentation analysed thoroughly, so if you ever need to go back and figure out why you included or excluded something, there’s a paper trail and a rational analysis behind it. – advises Alan Baghdasarayan, the head of BridgePoint Group’s Innovation Advisory team.

If your business is already claiming the R&DTI, it’s worth asking: do you know, line by line, why each cost is in or out of your claim? Could some of what’s excluded actually belong to another grant or incentive? And could you explain your R&D spend, with confidence, to a regulator, an investor or a buyer tomorrow? For many businesses, the honest answer only becomes clear once someone looks closely enough to ask.


If you have already claimed R&D for this FY or are preparing your claim, it’s worth taking a detailed look at your expenses before lodging it. BridgePoint Group has helped hundreds of companies legitimately maximise their claims. Reach out to Alan Baghdasarayan, who will provide a 30-minute complimentary call to discuss your case.

Talk To
Alan Baghdasarayan
DIRECTOR
Subscribe to our newsletter

Get informed about our business all the time, whatever you are. Read whenever you want.